Reports
Sale
Global Metabolomics Market Size, Share, Trends, Analysis: By Product and Services: Metabolomics Instruments, Metabolomics Bioinformatics Tools and Services; By Application: Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Others; By Indication; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Metabolomics Market Size
The global metabolomics market was valued at USD 2.5 billion in 2023, driven by the rising prevalence of chronic diseases across the globe. The market is anticipated to grow at a CAGR of 12.36% during the forecast period of 2024-2032 to achieve a value of USD 7.3 billion by 2032.
Metabolomics Market Outlook
- In pharmaceuticals and biotechnology, metabolomics is penetrating the market because of its applications in drug development, common diseases, and enabling technology, which provides better results and is faster.
- In June 2023, Waters Corporation advanced the Select SeriesTM MRT System, offering higher specificity and usefulness for metabolomics applications, which can be useful for the growing need for better resolution in metabolomics for drug discovery and clinical diagnostics.
- North America is expected to dominate the market for metabolomics owing to its superior healthcare system and investment in medical technology, while Europe is the second largest market due to liberal government funding and an emphasis on custom-computed treatments.
Metabolomics Market Overview
Metabolomics can be defined as a branch of science that deals with the analysis of metabolites in organisms to establish information on functioning cells as well as diseases. Biomarker discovery, drug development, toxicology, and determining the nutritional value of foods are some of the fields where it is commonly used. Metabolites are accurately quantified and identified by mass spectrometry, nuclear magnetic resonance spectroscopy, chromatography, or other techniques that are frequently used in the clinical and research fields.
Metabolomics Market Growth Drivers
Pharmaceutical and Biotechnology Research Boost the Market Growth
There is a growing application of metabolomics in the pharmaceutical and biotechnology industries to optimize drug discovery and development. It offers knowledge of drug actions, potency, and toxicity to enhance the drug pipeline. Scientists employ this technique to confirm drug targets, determine the effects of a particular drug on the candidate metabolism, and estimate its pharmacokinetics and toxicity. This information enhances the formulation process, lowers the occurrence of failures towards the end, and increases the probability of bringing new therapies and treatments on the market.
Increasing Prevalence of Chronic Disease to Foster Demand for Metabolomics Market
Globally, the prevalence of cancer, diabetes, and cardiovascular diseases, among others, has increased over time, demanding better diagnostic and treatment tools, including metabolomics.
For instance, the Centers for Disease Control and Prevention (CDC) reports that diabetes impacts 38.4 million individuals. Among them, 29.7 million have received a diagnosis, while 8.7 million cases remain undetected. These diseases are common causes of morbidity and mortality globally, thus necessitating better and more accurate diagnostic, assessment, and management procedures.
Metabolomics Market Trends
Integration of Multi-Omics
The combination of metabolomic profiling with other forms of omics is helping researchers gain a better understanding of the biological system, thus providing better diagnostic tools for diseases and therapeutic interventions. It is believed that this trend will further improve the importance and utilization of metabolomics in research and clinical practice.
Collaboration and Partnerships
Research collaborations between universities, industries, and research institutions are boosting the advancement of metabolomics. These associations are promoting the utilization and advancement of metabolomics in various fields.
Technological Advancements
Advanced technologies and equipment, coupled with improved data processing tools, are making metabolomics studies faster and more precise. These advancements are expected to make metabolomics more affordable and widely adopted in drug discovery, clinical diagnostics, and other areas.
Growing Use in Drug Discovery and Development
Metabolomics is rising to prominence in the realm of drug discovery and development in terms of target identification, drug action clarification, as well as the determination of drug output and risk profiles. Metabolite profiling helps researchers comprehend the pathways that differ in disease conditions, enhance the effectiveness of drugs, and discover the signs of toxicity. Oncology is among the areas that benefit from this approach since it helps identify the metabolic characteristics that may be linked to drug resistance and the subsequent creation of combination therapies.
Recent Developments in the Metabolomics Market
In September 2023, the National Institutes of Health (NIH) research grants allocated USD 50.3 million to the Multi-Omics for Health and Disease Consortium to support further multi-omics work in human health and disease. The consortium is expected to launch strategic approaches to clinical research with populations of ancestry as a source of complexity in its first year with USD 11 million worth funding. This project, in turn, funded by NHGRI, NCI, and NIEHS, involved processing samples at an omics production center and making data available to the scientific community to enhance the understanding of a particular disease and design treatments and new drugs.
In June 2023, Waters Corporation improved and expanded the SELECT SERIES™ MRT System, enhancing its specificity to extensively serve metabolomics, UPLC-MS/MS, and MSI specs in drug discovery. Modifications include 50% higher resolution, 300,000 FWHM resolution, a scan rate that is now three times faster, and mass value accuracy in parts per billion. The new REM gives scientists the ability to differentiate between analytes in biological fluid and tissue samples, improving the efficiency of metabolomics and MS imaging.
Metabolomics Market Segmentation
Market Breakup by Product and Services
- Metabolomics Instruments
- Separation Tools
- Detection Tools
- Metabolomics Bioinformatics Tools and Services
Market Breakup by Application
- Biomarker Discovery
- Drug Discovery
- Toxicology Testing
- Nutrigenomics
- Functional Genomics
- Personalized Medicine
- Other Applications
Market Breakup by Indication
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Inborn Errors of Metabolism
- Other Indications
Market Breakup by End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Metabolomics Market Share
Market Segmentation Based on Indication to Witness Substantial Growth
Based on the indication, the market is segmented into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. Among these, the use of metabolomics in cancer diagnosis and treatment is expected to gain more traction as it can provide early and accurate diagnostic capabilities, as well as individualized therapies for patients. Metabolomics yields real-time metabolic signatures that have been correlated with the precise changes that manifest in various types of cancer at different stages. This enables the detection of the disease at an early stage, providing patients with a unique therapeutic management plan that improves treatment results and reduces side effects.
Metabolomics Bioinformatics Tools and Services Anticipated to Have Largest Market Share Based on Product and Services
Based on the product and services, the market is divided into metabolomics instruments, and metabolomics bioinformatics tools and services. Metabolomic instruments are further divided into separation and detection tools. Among these, metabolomics bioinformatics tools and services are expected to lead the market share due to the large amount of data obtained in metabolomics studies. These tools are crucial for analysing and discovering trends from large amounts of data. As metabolomics broadens its applications to other sectors, its requirements will also increase to help researchers access significant data.
Metabolomics Market Analysis by Region
Based on the region, the market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Of these regions, North America is expected to dominate, owing to its developed healthcare system, high spending on healthcare, and pioneering investments in modern, advanced medical technologies.
Europe is a large market for metabolomics, particularly Germany, the United Kingdom, and France. Government support is highly favorable in the region, healthcare infrastructure is well developed, and recently, a trend toward more individualized treatments have emerged.
Leading Players in the Metabolomics Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Agilent Technologies, Inc.
The company was established in 1999 and is based in California, USA. It provides high-performing mass spectrometers such as the Agilent 6545XT AdvanceBio LC/Q-TOF for metabolite identification and quantification.
Thermo Fisher Scientific, Inc.
This Massachusetts, USA-based company was established in 1956. Its product range is primarily focused on high-resolution mass spectrometry, which features the Thermo Scientific Q Exactive and Orbitrap series.
Bruker Corporation
Founded in 1960 and headquartered in Massachusetts, USA. The company provides the latest mass spectrometry tools such as the Bruker timsTOF PRO and maXis II for ultra-high-resolution analysis.
Other companies include Shimadzu Corporation, Bio-Rad Laboratories Inc., Metabolon, Inc., Danaher Corporation, PerkinElmer Inc., Human Metabolome Technologies, and Bioanalytical Systems, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product and Services |
|
| Breakup by Application |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Metabolomics Market
- What was the global metabolomics market value in 2023?
- What is the global metabolomics market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What are the major factors aiding the global metabolomics market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global metabolomics market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the metabolomics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What is the market segmentation based on the product and services?
- What are the latest advancements in metabolomics instruments?
- What role do bioinformatics tools play in metabolomics analysis?
- What is the market breakup based on the mode of application?
- How is metabolomics transforming the drug discovery process?
- What are the emerging applications of metabolomics in functional genomics?
- What is the market segmentation based on the indication?
- What are the latest trends in metabolomics research for cancer?
- What are the potential metabolomic biomarkers for cardiovascular diseases?
- What is the market segmentation based on the end user?
- What are the benefits of metabolomics for drug development in pharmaceutical companies?
- What is the market breakup based on the region?
- How is the regulatory landscape in North America affecting the metabolomics market?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Metabolomics Market Overview
3.1 Global Metabolomics Market Historical Value (2017-2023)
3.2 Global Metabolomics Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Metabolomics Market Landscape*
5.1 Global Metabolomics Market: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Metabolomics Market: Product Landscape
5.2.1 Analysis by Product and Services
5.2.2 Analysis by Application
5.2.3 Analysis by Indication
6 Global Metabolomics Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Metabolomics Market Segmentation (2017-2032)
7.1 Global Metabolomics Market (2017-2032) by Product and Services
7.1.1 Market Overview
7.1.2 Metabolomics Instruments
7.1.2.1 Separation Tools
7.1.2.2 Detection Tools
7.1.3 Metabolomics Bioinformatics Tools and Services
7.2 Global Metabolomics Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Biomarker Discovery
7.2.3 Drug Discovery
7.2.4 Toxicology Testing
7.2.5 Nutrigenomics
7.2.6 Functional Genomics
7.2.7 Personalized Medicine
7.2.8 Other Applications
7.3 Global Metabolomics Market (2017-2032) by Indication
7.3.1 Market Overview
7.3.2 Cancer
7.3.3 Cardiovascular Disorders
7.3.4 Neurological Disorders
7.3.5 Inborn Errors of Metabolism
7.3.6 Other Indications
7.4 Global Metabolomics Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Pharmaceutical and Biotechnology Companies
7.4.3 Contract Research Organizations
7.4.4 Others
7.5 Global Metabolomics Market (2017-2032) by Region
7.5.1 Market Overview
7.5.2 North America
7.5.3 Europe
7.5.4 Asia Pacific
7.5.5 Latin America
7.5.6 Middle East and Africa
8 North America Metabolomics Market (2017-2032)
8.1 North America Metabolomics Market (2017-2032) by Product and Services
8.1.1 Market Overview
8.1.2 Metabolomics Instruments
8.1.2.1 Separation Tools
8.1.2.2 Detection Tools
8.1.3 Metabolomics Bioinformatics Tools and Services
8.2 North America Metabolomics Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Biomarker Discovery
8.2.3 Drug Discovery
8.2.4 Toxicology Testing
8.2.5 Nutrigenomics
8.2.6 Functional Genomics
8.2.7 Personalized Medicine
8.2.8 Other Applications
8.3 North America Metabolomics Market (2017-2032) by Country
8.3.1 United States of America
8.3.2 Canada
9 Europe Metabolomics Market (2017-2032)
9.1 Europe Metabolomics Market (2017-2032) by Product and Services
9.1.1 Market Overview
9.1.2 Metabolomics Instruments
9.1.2.1 Separation Tools
9.1.2.2 Detection Tools
9.1.3 Metabolomics Bioinformatics Tools and Services
9.2 Europe Metabolomics Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Biomarker Discovery
9.2.3 Drug Discovery
9.2.4 Toxicology Testing
9.2.5 Nutrigenomics
9.2.6 Functional Genomics
9.2.7 Personalized Medicine
9.2.8 Other Applications
9.3 Europe Metabolomics Market (2017-2032) by Country
9.3.1 United Kingdom
9.3.2 Germany
9.3.3 France
9.3.4 Italy
9.3.5 Others
10 Asia Pacific Metabolomics Market (2017-2032)
10.1 Asia Pacific Metabolomics Market (2017-2032) by Product and Services
10.1.1 Market Overview
10.1.2 Metabolomics Instruments
10.1.2.1 Separation Tools
10.1.2.2 Detection Tools
10.1.3 Metabolomics Bioinformatics Tools and Services
10.2 Asia Pacific Metabolomics Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Biomarker Discovery
10.2.3 Drug Discovery
10.2.4 Toxicology Testing
10.2.5 Nutrigenomics
10.2.6 Functional Genomics
10.2.7 Personalized Medicine
10.2.8 Other Applications
10.3 Asia Pacific Metabolomics Market (2017-2032) by Country
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 ASEAN
10.3.5 Australia
10.3.6 Others
11 Latin America Metabolomics Market (2017-2032)
11.1 Latin America Metabolomics Market (2017-2032) by Product and Services
11.1.1 Market Overview
11.1.2 Metabolomics Instruments
11.1.2.1 Separation Tools
11.1.2.2 Detection Tools
11.1.3 Metabolomics Bioinformatics Tools and Services
11.2 Latin America Metabolomics Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Biomarker Discovery
11.2.3 Drug Discovery
11.2.4 Toxicology Testing
11.2.5 Nutrigenomics
11.2.6 Functional Genomics
11.2.7 Personalized Medicine
11.2.8 Other Applications
11.3 Latin America Metabolomics Market (2017-2032) by Country
11.3.1 Brazil
11.3.2 Argentina
11.3.3 Mexico
11.3.4 Others
12 Middle East and Africa Metabolomics Market (2017-2032)
12.1 Middle East and Africa Metabolomics Market (2017-2032) by Product and Services
12.1.1 Market Overview
12.1.2 Metabolomics Instruments
12.1.2.1 Separation Tools
12.1.2.2 Detection Tools
12.1.3 Metabolomics Bioinformatics Tools and Services
12.2 Middle East and Africa Metabolomics Market (2017-2032) by Application
12.2.1 Market Overview
12.2.2 Biomarker Discovery
12.2.3 Drug Discovery
12.2.4 Toxicology Testing
12.2.5 Nutrigenomics
12.2.6 Functional Genomics
12.2.7 Personalized Medicine
12.2.8 Other Applications
12.3 Middle East and Africa Metabolomics Market (2017-2032) by Country
12.3.1 Saudi Arabia
12.3.2 United Arab Emirates
12.3.3 Nigeria
12.3.4 South Africa
12.3.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Grants Analysis
15.1 Analysis by Year
15.2 Analysis by Amount Awarded
15.3 Analysis by Issuing Authority
15.4 Analysis by Grant Application
15.5 Analysis by Funding Institute
15.6 Analysis by Departments
15.7 Analysis by Recipient Organization
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Strategic Initiatives
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Market Share Analysis, By Region (Top 5 Companies)
18.1.1 Market Share Analysis: Global
18.1.2 Market Share Analysis: North America
18.1.3 Market Share Analysis: Europe
18.1.4 Market Share Analysis: Asia Pacific
18.1.5 Market Share Analysis: Others
18.2 Agilent Technologies, Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Company News and Development
18.2.5 Certifications
18.3 Thermo Fisher Scientific, Inc.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Company News and Development
18.3.5 Certifications
18.4 Bruker Corporation
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Company News and Development
18.4.5 Certifications
18.5 Shimadzu Corporation
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Company News and Development
18.5.5 Certifications
18.6 Bio-Rad Laboratories, Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Company News and Development
18.6.5 Certifications
18.7 Metabolon, Inc.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Company News and Development
18.7.5 Certifications
18.8 Danaher Corporation
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic
18.8.4 Company News and Development
18.8.5 Certifications
18.9 PerkinElmer Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Company News and Development
18.9.5 Certifications
18.10 Human Metabolome Technologies
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Company News and Development
18.10.5 Certifications
18.11 Bioanalytical Systems, Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Company News and Development
18.11.5 Certifications
19 Global Metabolomics Market – Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER